• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 疫苗的开发、获取和公平性。

SARS-CoV-2 vaccine development, access, and equity.

机构信息

International Vaccine Institute, Seoul, South Korea.

出版信息

J Exp Med. 2020 Nov 2;217(11). doi: 10.1084/jem.20201288.

DOI:10.1084/jem.20201288
PMID:33064151
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7563686/
Abstract

Over the past 9 mo, with 34 million infections and 1 million deaths, the COVID-19 pandemic has levied a grisly toll. Some countries, through political will and social organization, have successfully reduced the number of infections and deaths, but the global scale of loss reflects the difficulty of translating these approaches in other countries. An effective SARS-CoV-2 vaccine presents a technological solution to the failure of social and political ones. Vaccines are, however, not a silver bullet, but a safe, cost-effective, and globally applicable tool that will require a substantial effort-cooperation, commitment, time, and funding-to be effective.

摘要

在过去的 9 个月里,COVID-19 大流行已造成 3400 万人感染和 100 万人死亡,造成了可怕的损失。一些国家通过政治意愿和社会组织成功地降低了感染和死亡人数,但全球范围内的损失反映了将这些方法转化为其他国家的方法的困难。有效的 SARS-CoV-2 疫苗为社会和政治失败提供了技术解决方案。然而,疫苗不是万能的,而是一种安全、具有成本效益且全球适用的工具,需要付出巨大的努力——合作、承诺、时间和资金——才能发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7515/7563686/b1ad8746fb76/JEM_20201288_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7515/7563686/b1ad8746fb76/JEM_20201288_Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7515/7563686/b1ad8746fb76/JEM_20201288_Fig1.jpg

相似文献

1
SARS-CoV-2 vaccine development, access, and equity.SARS-CoV-2 疫苗的开发、获取和公平性。
J Exp Med. 2020 Nov 2;217(11). doi: 10.1084/jem.20201288.
2
Keeping track of the SARS-CoV-2 vaccine pipeline. 跟踪 SARS-CoV-2 疫苗研发管线。
Nat Rev Immunol. 2020 Nov;20(11):650. doi: 10.1038/s41577-020-00455-1.
3
COVID-19 Vaccine: A comprehensive status report.新型冠状病毒肺炎疫苗:全面现状报告。
Virus Res. 2020 Oct 15;288:198114. doi: 10.1016/j.virusres.2020.198114. Epub 2020 Aug 13.
4
What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist.詹纳和巴斯德会如何应对新冠冠状病毒?一位疫苗学家的呼吁。
Front Immunol. 2020 Aug 26;11:2173. doi: 10.3389/fimmu.2020.02173. eCollection 2020.
5
Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.基于类似冠状病毒的实验结果开发 SARS-CoV-2 疫苗的潜在佐剂。
Int Immunopharmacol. 2020 Sep;86:106717. doi: 10.1016/j.intimp.2020.106717. Epub 2020 Jun 18.
6
Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development.在严重急性呼吸综合征冠状病毒2疫苗研发中平衡权宜性与科学严谨性
J Infect Dis. 2020 Jun 29;222(2):180-182. doi: 10.1093/infdis/jiaa234.
7
DNA vaccine protection against SARS-CoV-2 in rhesus macaques.DNA 疫苗对食蟹猴 SARS-CoV-2 的保护作用。
Science. 2020 Aug 14;369(6505):806-811. doi: 10.1126/science.abc6284. Epub 2020 May 20.
8
SARS-CoV-2 immunogenicity at the crossroads.十字路口的新型冠状病毒2型免疫原性
Allergy. 2020 Jul;75(7):1822-1824. doi: 10.1111/all.14360. Epub 2020 May 25.
9
What the immune response to the coronavirus says about the prospects for a vaccine.对冠状病毒的免疫反应揭示了疫苗的前景。
Nature. 2020 Sep;585(7823):20-21. doi: 10.1038/d41586-020-02400-7.
10
Impact of glycoscience in fighting Covid-19.糖科学在抗击新冠疫情中的作用
Glycoconj J. 2020 Aug;37(4):511-512. doi: 10.1007/s10719-020-09929-9.

引用本文的文献

1
Development of nucleic acid-based vaccines against dengue and other mosquito-borne flaviviruses: the past, present, and future.登革热及其他蚊媒黄病毒核酸疫苗的研发:过去、现在与未来。
Front Immunol. 2025 Jan 7;15:1475886. doi: 10.3389/fimmu.2024.1475886. eCollection 2024.
2
Death Reporting in Breakthrough and Unvaccinated SARS-CoV-2 Infection Cases.突破性感染和未接种疫苗的 SARS-CoV-2 感染病例的死亡报告。
Disaster Med Public Health Prep. 2023 Mar 20;17:e359. doi: 10.1017/dmp.2023.4.
3
Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein.

本文引用的文献

1
COVID-19 herd immunity: where are we?COVID-19 群体免疫:我们在哪里?
Nat Rev Immunol. 2020 Oct;20(10):583-584. doi: 10.1038/s41577-020-00451-5.
2
Evolution of the COVID-19 vaccine development landscape.新冠疫苗研发格局的演变。
Nat Rev Drug Discov. 2020 Oct;19(10):667-668. doi: 10.1038/d41573-020-00151-8.
3
Developing Safe and Effective Covid Vaccines - Operation Warp Speed's Strategy and Approach.开发安全有效的新冠疫苗——“极速行动”计划的策略与方法。
表达S1-N融合蛋白的腺病毒载体新冠病毒疫苗。
Antib Ther. 2022 Jul 8;5(3):177-191. doi: 10.1093/abt/tbac015. eCollection 2022 Jul.
4
Advocating for Greater Inclusion of Marginalized and Forgotten Populations in COVID19 Vaccine Rollouts.倡导在 COVID19 疫苗接种中更加包容被边缘化和被遗忘的人群。
Int J Public Health. 2021 Oct 11;66:1604036. doi: 10.3389/ijph.2021.1604036. eCollection 2021.
5
The Vaccination Process against the COVID-19: Opportunities, Problems and Support.针对新冠病毒的疫苗接种过程:机遇、问题与支持
Healthcare (Basel). 2021 Sep 6;9(9):1165. doi: 10.3390/healthcare9091165.
6
Vaccine development for emerging infectious diseases.新发传染病疫苗的研发。
Nat Med. 2021 Apr;27(4):591-600. doi: 10.1038/s41591-021-01301-0. Epub 2021 Apr 12.
7
Supply and delivery of vaccines for global health.疫苗的供应和交付用于全球健康。
Curr Opin Immunol. 2021 Aug;71:13-20. doi: 10.1016/j.coi.2021.03.009. Epub 2021 Apr 10.
N Engl J Med. 2020 Oct 29;383(18):1701-1703. doi: 10.1056/NEJMp2027405. Epub 2020 Aug 26.
4
Vaccination against SARS-CoV-2 and disease enhancement - knowns and unknowns.接种 SARS-CoV-2 疫苗与疾病增强——已知与未知。
Expert Rev Vaccines. 2020 Aug;19(8):691-698. doi: 10.1080/14760584.2020.1800463. Epub 2020 Aug 24.
5
The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.迈向 COVID-19 群体免疫的漫长道路:疫苗平台技术和大规模免疫策略。
Front Immunol. 2020 Jul 21;11:1817. doi: 10.3389/fimmu.2020.01817. eCollection 2020.
6
Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model.为被忽视疾病开发新的卫生技术:管道式投资组合审查与成本模型
Gates Open Res. 2018 Aug 22;2:23. doi: 10.12688/gatesopenres.12817.2. eCollection 2018.